New all-oral regimen improves treatment convenience for AML patients
Sanatate
Weill Cornell Medicine Jun 3 2026 The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires repeated hospital or office visits for intravenous treatment. In the international phase 1/phase 2 trial led by researchers at Weill Cornell Medicine, NewYork-Presbyterian, The University of Texas MD Anderson Cancer Center and Yale University, patients took a
din zilele anterioare